| Primary information |
|---|
| sequence ID | Seq_6301 |
| Peptide sequence | QLGLPGPPDVPDHAAYHPF |
| CancerPDF_ID | CancerPDF_ID50, CancerPDF_ID784, CancerPDF_ID1061, CancerPDF_ID3030, CancerPDF_ID6546, CancerPDF_ID8569, CancerPDF_ID11059, |
| PMID | 16896061,19795908,16395409,21136997,24982608,23667664,26993605 |
| Protein Name | Inter-alpha-trypsin inhibitor heavy chain H8,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H6,Inter-alpha-trypsin inhibitor heavy chain H4,Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4 |
| UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
| Fluid | Serum,Plasma,Serum,Plasma,Urine,Serum,Serum |
| M/Z | 2028.01,676.66,2028.01,2026.9901,NA,2026.99,2026.8 |
| Charge | 1,3,1,1,NA,1,NA |
| Mass (in Da) | 2027.99,NA,NA,NA,NA,2029.26,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,Nano-LC-MS,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,MS/MS,FT-ICR MS/MS + nano-HPLC,LTQ-Orbitrap-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,NA,NA,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,0.01,NA,less than 0.000009 |
| CancerPDF_ID | CancerPDF_ID50, CancerPDF_ID784, CancerPDF_ID1061, CancerPDF_ID3030, CancerPDF_ID6546, CancerPDF_ID8569, CancerPDF_ID11059, |
| p-Value | 1.00E-05,NA,less than 0.05,NA,NA,NA,less than 0.05 |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),"GPM search engine, MASCOT",MASCOT,SEQUEST |
| Length | 19,19,19,19,19,19,19 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Normal,Ovarian cancer,"Breast cancer, Lung cancer, Rectal cancer",Esophageal squamous cell carcinoma (ESCC) |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,IPI 3.71 Human Database ,NA,IPI Human Database (3.45) |
| Modification | NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",27 healthy individuals,6 Ovarian cancer patients and 6 normal individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",for training 100 ESCC patients and 98 healthy individuals were used and for validation 101 ESCC patients and 98 healthy individuals were used |
| Regulation | NA,NA,NA,NA,Uniquely present in case of urine of ovarian cancer patients,NA,"Upregulated in ESCC patients vs control with mean intensity in cancer as 2,730.99 and mean intensity in normal 1,290.54" |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,NA,NA,external cross validation done |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,97% on training dataset and 97.3 on validation dataset |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,95.92% on training dataset and 100% on validation dataset |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |